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The peptide Tyr-Ser-Glu-Ala-Thr-Val-Ala-Glu-Ser-Asp-Ser-Phe (the predicted C-terminal 11 amino acids 
of the TMV 30kDa open reading frame plus an additional N-terminal Tyr residue) was synthesized by solid 
phase methods and used to raise antisera in rabbits. These antisera precipitated 4 major proteins (p30, ~28, 
p19 and 18SkDa) from in vitro translation products of TMV short rod RNA, but only one, of apparent 
M, = 30500, from TMV-infected tobacco protoplasts. This protein was made between 8 and 16 h post 
infection, and had [35S]Met-labelled tryptic peptides identical to those of in vitro synthesized ~30. 
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1. INTRODUCTION 
The coding capacity of many plant viruses with 
messenger sense RNA genomes has been studied by 
using viral RNA to direct protein synthesis in vitro. 
Major translation products often correspond to 
predicted open reading frames (ORFs) where the 
RNA sequence is known, but detection of non- 
structural proteins to prove their identity with in 
vitro translation products has proved difficult. An 
attractive new approach to this problem, given the 
RNA sequence, is to use synthetic peptides 
predicted to occur in the amino acid sequence to 
raise antisera capable of precipitating the native 
protein [l]. We have used this method to produce 
antisera to protein p30 of TMV: the predicted pro- 
duct of an open reading frame (ORF) encoded by 
nucleotide residues 4903-5706 on TMV RNA 
(76.7-89.2% of the genome from the 5 ‘-end) [2]. 
Genetic experiments implicate a product of this 
ORF in the spreading of necrotic local lesions 
[3,4], but at least 3, and possibly as many as 6 
overlapping protein products can be found in vitro 
[5]. A protein of ikf, = 30000-31000 has been 
reported in TMV infected protoplasts [6] and 
leaves [7], but its ephemeral nature has prevented 
further characterisation, and leaves open the ex- 
istence of other products. We expected that an- 
tisera to p30 peptides would be useful as probes to 
identify and enumerate p30-related proteins in 
vivo, and for other studies. 
2. MATERIALS AND METHODS 
t To whom correspondence should be addressed 
2.1. Solid phase peptide synthesis 
The desired peptide was synthesized on a cross- 
linked polydimethylacrylamide resin (1 g) func- 
tionalized with internal reference t-butoxycarbonyl 
(Boc)-norleucine (0.12 meq/g) (UCB Bioproducts, 
Brussels) as follows [8,9]: 
(i) cleavage of the Boc-groups using N- 
HCl/AcOH and neutralisation with 10% 
diisopropylethylamine in freshly distilled 
DMF; 
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(ii) acylation with the reversible linkage agent, p- 
hydroxymethylphenoxyacetic acid trichloro- 
phenyl ester in the presence of hydroxyben- 
zotriazole (1 eq.) (70 min); 
(iii) esterification with freshly prepared fluorenyl- 
methoxycarbonyl (Fmoc)-Phe anhydride in 
the presence of N-methylmorpholine (1 eq.) 
and 4-dimethylaminopyridine [lo] (30 min); 
(iv) a cycle of deprotection with 20010 piperidine in 
DMF (3 + 7 min); followed by acylation with 
a 6-fold excess of the appropriately protected 
Fmoc-amino acid derivatives in DMF 
(60 min). 
An aliquot (0.104 g) of the dried resin was cleav- 
ed with 95% aq. CF3COzH for 1.5 h and the pro- 
duct (18.6 pmol, 98% cleavage) chromatographed 
on DEAE-cellulose (DE52) using a linear gradient 
of 0.01-0.3 M aq. N&HCOs, pH 8.1. The major 
peak was collected, freeze dried (yield = 
13.82 pmol = 74%) and characterized by high per- 
formance liquid chromatography (HPLC) and 
amino acid analysis (fig.1). 
2.2. Coupling and immunisation 
o-Toluidine (3.4 mg) was bis-diazotised as 
described for benzimide [l l] and used to couple 
the peptide (6 mg) to carrier bovine serum albumin 
0 l- 
co 
RI 
8 
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Fig. 1. Analytical reversed-phase HPLC was carried out 
on,uBondapak CIS using a linear gradient of lo-25crlo B
over 20 min when pump A was delivering 0.01 M 
NI-bOAc (pH 4.5) and pump B 90% acetonitrile/lO% 
A, with a flow rate of 1.5 ml/min. The profile at 230 nm 
was similar to that shown at 278 nm. Amino acid 
analysis of the DE 52 purified product showed: Phe 
0.90, Ser 2.49, Asp 1.00, Glu 2.09, Ala 2.00, Val 0.99, 
Thr 0.86 and Tyr 0.94. 
(15 mg) [ 11. New Zealand White rabbits were im- 
munized by intramuscular or multiple sub- 
cutaneous injections of one-eighth aliquots of con- 
jugate (0.5 ml) in Freund’s complete adjuvant 
(1 ml) and up to two intramuscular booster injec- 
tions of half these amounts at various intervals up 
to 4 months. 
2.3. In vitro translation 
A crude TMV short rod preparation was made 
by ‘differential resuspension’ and CsCl-banding 
essentially as in [12]. Electron microscopy of the 
particles showed 58% less than half length (pro- 
bably mostly broken rods) and 26% full length 
(total scored, 159). RNA was extracted, translated 
[ 131 and products fingerprinted as in [5]. 
2.4. Protoplast procedures and immuno- 
precipitation 
Protoplasts isolated from N. tabacum cv Xanthi 
nc were inoculated with TMV RNA using the 
PEG-Ca2+ method [14] and incubated at 5 x 
10S/ml in medium modified from [15] containing 
0.3-1.0 mCi/ml [35S]Met (> 1000 Ci/mmol, Am- 
ersham). Detailed procedures will be described 
elsewhere (in preparation). Detergent lysis and im- 
munoprecipitation with carrier Pansorbin (Calbio- 
them) used published procedures [16,171 indicated 
in the text and figure legends. 
3. RESULTS 
We previously showed that the 30kDa ORF of 
TMV is translated in vitro into at least 3 overlapp- 
ing proteins with staggered N termini and probably 
identical C termini [5], so a synthetic peptide cor- 
responding to the C terminus of the 30kDa ORF 
(which is hydrophilic and so may be exposed in the 
native protein) should elicit antibodies capable of 
precipitating all 3 proteins, and any other C coter- 
minal products. Peptides corresponding to protein 
termini have been used previously to raise antisera 
to native proteins [l]. Thus, the sequence chosen 
for synthesis was the C terminal undecapeptide of 
p30: Ser-Glu-Ala-Thr-Val-Ala-Glu-Ser-Asp-Ser- 
Phe [2], which was synthesized with an extra Tyr 
residue at the N terminus, coupled to BSA via this 
tyrosine using bis-diazotised o-toluidine, and used 
to raise antisera as described in section 2. 
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3. I. Immu~o~rec~~ita~Ie products of the 30kDa 
ORF in vitro 
Antisera prepared from four rabbits immunised 
by different protocols all precipitated 4 major pro- 
teins from the reticulocyte lysate translation pro- 
ducts of RNA isolated from a short rod-enriched 
virus preparation (fig.2). These comigrated with in 
vitro products whose synthesis was resistant to 
m’GTP, a characteristic of products of the 30kDa 
ORF [5,7,18]. The 3 largest of these proteins 
(known as ~30, p28 and p19 from their molecular 
masses) have been shown by peptide mapping to be 
overlapping translation products of the 30kDa 
ORF [5]; this experiment confirms their derivation 
and relationship to the fourth protein (18.5 kDa) 
F 2 3 T 4 x 
and proves that all 4 proteins are C coterminal, as 
was previously inferred. Control experiments 
showed this precipitation to be specific since it was 
blocked by preincubation of antisera with excess 
peptide (qv fig.3), so distinguishi~ it from a 
variable background precipitation of additional 
proteins by immune antisera, or of the p30 family 
by preimmune or irrelevant (such as antiferritin) 
antisera. Eackgrounds were reduced using condi- 
tions as in [17] rather than those in [16], but yields 
were also reduced. 
3.2, Characterisation of a product of the 30kDa 
ORF in vivo 
In order to screen for the tr~slation products of, 
Fig.2, In vitro products of TMV ‘short rod’ RNA translation in the messenger dependent reticulocyte lysate, 
immunoprecipitated as in [17]. z‘, starting material; M, markers (88kDa, 56kDa (doublet), 40kDa and 21kDa); F, anti- 
ferritin antiserum; T, TMV ~tiserum; 1,2,3,4, antipeptide antisera from different rabbits. 
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Fig.3. Detergent lysates of tobacco protoplasts infected 
with TMV RNA, or mock infected, 28 h previously were 
immunoprecipitated as in (161. S, starting material; P, 
preimmune serum; I, immune serum (R90); IB, I, 
preincubated with excess peptide (3 pg//cl of serum). In 
vitro, reticulocyte translation of ‘short rod’ RNA in the 
presence of 1 mM m’GTP (major products arrowed on 
the left). Arrowhead on right denotes a specifically 
immunoprecipitated protein of h4, -30000 in infected 
cells. 
the 30kDa ORF in vivo, immunoprecipitates were 
prepared from detergent lysates of tobacco pro- 
toplasts infected 28 h previously with TMV RNA, 
and from mock infected controls. Preliminary ex- 
periments revealed limited amounts of ~30, so we 
used the protocol in [16] and prepared 
35 lo’-10’ cpm of S- labelled trichloroacetic acid 
precipitable protoplast sample for each experi- 
ment, distinguishing the background of non- 
specific material from specific immunoprecipita- 
tion with the appropriate controls using preim- 
mune serum and immune serum preincubated with 
the synthetic peptide. Fig.3 shows that a protein of 
about A4, = 30 500 appeared in immunoprecipitates 
made using immune serum and a lysate of infected 
cells, but not in lysates of mock infected cells or 
with preimmune or peptide blocked sera. It seemed 
likely that this protein was an in vivo product of 
the 30kDa open reading frame, although fig.3 
shows that it did not exactly comigrate with the in 
vitro synthesized marker ~30. A preliminary ex- 
periment showed that mixing in vitro synthesized 
p30 with protoplasts followed by lysis and im- 
munoprecipitation did not alter its mobility to the 
in vivo position; nevertheless tryptic peptide mapp- 
ing (fig.4) showed conclusively that the 
[35S]methionine-labelled maps of in vitro and in 
vivo synthesized p30 were indistinguishable. 
Twenty-eight hours is late in TMV infection, so 
to examine the possibility that other p30-related 
proteins were made at other times, samples of 
mock-infected and infected protoplasts were im- 
munoprecipitated at 8, 16, 24 and 32 h post infec- 
tion. The results (fig.5) showed that the amount of 
p30 present increased sharply between 8 h (when it 
was barely detectable) and 16 h, and that little ad- 
ditional accumulation occurred after that. No 
other p30-related proteins were detectable at any 
time. This result suggests that p30 synthesis begins 
close to the onset of exponential growth at about 
8 hpi [ 151, but that there is little or no nett syn- 
thesis of p30 late in infection, unlike coat protein. 
More detailed experiments would be needed to 
determine the kinetics of p30 synthesis relative to 
those of the other TMV proteins. 
4. DISCUSSION 
These results show that antisera to TMV protein 
p30 can be successfully raised by the synthetic pep- 
tide strategy. Solid phase methods have now ad- 
vanced to the point where almost any desired pep- 
tide can be synthesized routinely. Therefore this 
method may prove very useful in the identification 
and analysis of plant viral proteins, where the gene 
sequence is often more accessible than the gene 
product. 
Our analysis of products of in vitro translation 
using the anti-p30 antisera confirms previous work 
showing a family of overlapping proteins [5]. 
Whereas enumeration of these proteins previously 
depended on exhaustive peptide mapping, the an- 
tisera precipitate all these related proteins in a 
single experiment, and prove that they are C 
coterminal. 
In contrast, similar experiments reveal only a 
single product in vivo. This protein appears to 
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Fig.4. Tryptic peptide maps of [35S]Met-labelled p30 immunoprecipitated from infected tobacco protoplasts (A) 
compared with that of the 30 kDa product of in vitro translation of ‘short rod’ RNA (B). Spot numbering as in [5]. 
migrate slightly slower on gels than in vitro syn- 
thesized ~30, but tryptic peptide mapping (fig.4) 
shows no detectable differences in the Met- 
containing peptides. The mobility difference could 
be due to a post-translational modification, but if 
so the modification is probably not within a Met- 
containing tryptic peptide. No smaller p30-related 
proteins were detected in any of our protoplast ex- 
periments, although p30 itself was expressed at a 
moderately low level (in the range of O.l-0.01% of 
the total trichloroacetic acid-precipitable 35S incor- 
poration), and we estimate that our experiments 
would be insufficiently sensitive to detect expres- 
sion of other products at below a few percent of 
this level. The discrepancy between the in vitro and 
in vivo results may be due to template breakdown 
in vitro, but if so the previously documented 
similarities between p30 synthesis in vitro and that 
of the smaller proteins [5,18] suggest hat the in 
vitro expression of p30 itself may not properly 
reflect the in vivo mechanism. Alternatively, the 
short rod RNAs which direct synthesis of the 
smaller p30-related proteins may be generated in 
vivo by errors in subgenomic RNA synthesis, but 
their protein products may be non-functional and 
rapidly degraded. 
We recently learned 
similar methods have 
results. Their work is 
v91. 
that other workers using 
obtained broadly similar 
being reported elsewhere 
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Fig.5. Time course of [35S]Met-labelled p30 synthesis in 
TMV-infected tobacco protoplasts. M, mock infected; I, 
infected. Positions of in vitro synthesized markers on the 
left, that of coat protein synthesized in an aliquot of the 
same protoplasts labelled with [‘H]Leu on the right. 
Labelling was continuous; total trichloroacetic acid- 
precipitate incorporation increased linearly for 16 h and 
at about 50% of the initial rate for the next 16 h. 
REFERENCES 
VI 
VI 
Walter, G., Scheidtmann, K.-H., Carbone, A., 
Laudano, A.P. and Doolittle, R.F. (1980) Proc. 
Natl. Acad. Sci. USA 77, 5197-5200. 
Goelet, P., Lomonossoff, G.P., Butler, P.J.G., 
Akam, M.E., Gait, M. J. and Karn, J. (1982) Proc. 
Natl. Acad. Sci. USA 79, 5818-5822. 
131 
141 
151 
PI 
171 
181 
191 
[lOI 
1111 
WI 
1131 
1141 
1151 
WI 
H71 
[I81 
1191 
Leonard, D. and Zaitlin, M. (1982) Virology 117, 
416-424. 
Zimmern, D. and Hunter, T. (1983) EMBO 
Journal, in press. 
Hunter, T., Jackson, R. and Zimmern, D. (1983) 
Nucleic Acids Res. 11, 801-821. 
Beier, H., Mundry, K.W. and Issinger, O.-G. 
(1980) Intervirology 14, 292-299. 
Joshi, S., Pleij, C.W.A., Haenni, A.-L., 
Chapeville, F. and Bosch, L. (1983) Virology 127, 
100-111. 
Arshady, R., Atherton, E., Clive, D.L.J. and 
Sheppard, R.C. (1981) J. Chem. Sot. Perkin 1, 
529-537. 
Atherton, E., Logan, C.J. and Sheppard, R.C. 
(1981) J. Chem. Sot. Perkin 1, 538-546. 
Atherton, E., Benoiton, N.L., Brown, E., 
Sheppard, R.C. and Williams, B.J. (1981) J. 
Chem. Sot. Chem. Comm. 336-337. 
Bassiri, R.M. and Utiger, R.D. (1972) 
Endocrinology 90, 722-727. 
Whitfeld, P.R. and Higgins, T.J.V. (1976) 
Virology 71, 471-485. 
Pelham, H.R.B. and Jackson, R.J. (1976) Eur. J. 
Biochem. 67, 247-256. 
Dawson, J.R.O., Dickerson, P.E., King, J.M., 
Trim, A.R.H. and Watts, J.W. (1978) Z. 
Naturforsch. 33C, 548-551. 
Aoki, S. and Takebe, I. (1969) Virology 39, 
439-448. 
Papkoff, J., Lai, M.H.-T., Hunter, T. and Verma, 
I.M. (1981) Cell 27, 109-119. 
Semler, B.L., Hanecak, R., Dorner, A. J., 
Anderson, C.W. and Wimmer, E. (1983) Virology 
126, 624-635. 
Pelham, H.R.B. (1979) FEBS Lett. 100, 195-199. 
Ooshika, I., Watanabe, Y., Meshi, T., Okada, Y., 
Igano, K., Inouye, K. and Yoshida, N. (1983) 
Virology, in press. 
360 
